September 21, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) the leading global biotechnology company focused on rare diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for FIRAZYR® (icatibant injection), for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE.
7353/Zenith- answer the bell with an oral solution, and threaten to capture major market share- bring competitors to the table.....Q4 18.....
Get it done Jon, Tom, Babu, BOD......